• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Japan Depression Screening Mental Health Market

    ID: MRFR/HC/54518-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    Japan Depression Screening Mental Health Market Research Report By Indication (Major Depressive Disorder, Anxiety Distress, Bipolar Disorder, Psychotic Disorders, Others), By Diagnosis (Psychological Tests, Blood Tests, Pharmacogenomic Testing, Others) and By End User (Hospitals and Clinics, Home-based, Research and Academic Institutes)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Japan Depression Screening Mental Health Market Research Report - Forecast to 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    Japan Depression Screening Mental Health Market Summary

    The Japan Depression Screening Mental Health market is projected to grow significantly over the next decade.

    Key Market Trends & Highlights

    Japan Depression Screening Mental Health Key Trends and Highlights

    • The market valuation is expected to increase from 34.5 USD Million in 2024 to 71 USD Million by 2035.
    • A compound annual growth rate (CAGR) of 6.79 percent is anticipated from 2025 to 2035.
    • This growth reflects a rising awareness of mental health issues among the Japanese population.
    • Growing adoption of digital mental health solutions due to increased government initiatives is a major market driver.

    Market Size & Forecast

    2024 Market Size 34.5 (USD Million)
    2035 Market Size 71 (USD Million)
    CAGR (2025-2035) 6.79%

    Major Players

    Mizuho Financial Group, Mitsubishi Tanabe Pharma, Astellas Pharma, Fujitsu, Sony, iTHRIVE, Santen Pharmaceutical, NTT Data, Eisai, Otsuka Pharmaceutical, Fujifilm, LINE Corporation, Takeda Pharmaceutical, Daiichi Sankyo, Shionogi

    Japan Depression Screening Mental Health Market Trends

    The Japan Depression Screening Mental Health Market is experiencing several important trends shaped by cultural, technological, and healthcare system factors. One notable trend is the growing awareness and acceptance of mental health issues, particularly depression, which has been spurred by recent public health campaigns and educational programs. The Japanese government has been promoting mental health initiatives, encouraging screenings for depression in workplaces and educational institutions, thus reducing stigma and fostering a more supportive environment for those seeking help. Technological advancements play a key role in this market as well.

    The integration of digital health solutions and telehealth services is becoming increasingly popular, making it easier for individuals to access screening tools and professional support from the comfort of their homes. Mobile applications and online platforms for self-assessment are gaining traction, offering users immediate feedback on their mental health status. This trend is especially important in Japan, where traditional healthcare settings can sometimes be intimidating for individuals. There are significant opportunities to be explored in the realm of preventive care and early intervention.

    The Japanese population is aging, leading to an increased demand for mental health services that address the unique challenges faced by older adults.

    There is a strong potential to develop specialized screening programs tailored to this demographic, helping to identify and treat depression early on. In recent times, collaboration between government bodies, private healthcare providers, and mental health organizations more prominent, aiming to create comprehensive care models that incorporate screenings and treatments. This shift indicates a focused effort to enhance mental health care access and quality in Japan, signifying a promising outlook for the future of the depression screening mental health market in the region.

    Japan Depression Screening Mental Health Market Drivers

    Market Segment Insights

    Japan Depression Screening Mental Health Market Segment Insights

    Japan Depression Screening Mental Health Market Segment Insights

    Depression Screening Mental Health Market Indication Insights

    Depression Screening Mental Health Market Indication Insights

    The Japan Depression Screening Mental Health Market focuses on various indications that are critical in diagnosing and treating mental health issues. Among these indications, Major Depressive Disorder is particularly prominent, as it constitutes a significant percentage of mental health cases within the country. The high prevalence of this disorder underlines the necessity for effective screening methods and therapeutic interventions, contributing to a growing awareness of mental health. Anxiety Distress also plays a critical role in the overall market, as it often coexists with Major Depressive Disorder, thereby complicating treatment modalities.

    The attention given to anxiety-related symptoms in screening tools reflects the interconnected nature of mood disorders.

    Bipolar Disorder, while less common than Major Depressive Disorder and Anxiety Distress, is still significant due to its complex presentation and the need for tailored therapeutic approaches. The market recognizes the importance of precise screening for this disorder to ensure effective management and reduce the overall burden on healthcare systems. Psychotic Disorders represent another pivotal indication, necessitating urgent and accurate diagnosis; the existence of these disorders stresses the importance of comprehensive screening protocols that can differentiate between various psychological conditions. 

    Lastly, the "Others" category encapsulates a wide range of depressive and anxiety-related conditions that may not fit into the more recognized categories. The ongoing research and advancements in mental health practices within Japan encourage the development of increasingly nuanced screening methods to address the diverse needs of the population.

    Depression Screening Mental Health Market Diagnosis Insights

    Depression Screening Mental Health Market Diagnosis Insights

    The Diagnosis segment within the Japan Depression Screening Mental Health Market encompasses various methodologies that are crucial for effective identification and management of depression. Psychological Tests hold a significant place in this landscape, as they provide valuable insights into a patient's mental state, enabling healthcare professionals to devise tailored treatment plans. Blood Tests are emerging as an important aspect, offering potential biological markers of depression, thereby enhancing diagnostic accuracy. Pharmacogenomic Testing facilitates personalized medicine by assessing how individuals metabolize medications, which is essential in determining the most effective treatment strategies.

    Other diagnostic approaches also complement this segment, contributing to a more comprehensive assessment of depression. The growing emphasis on early detection and personalized care in Japan is driving innovations in diagnostic tools, aligning with the increased awareness of mental health issues among the population. The combination of these methodologies not only supports accurate diagnosis but also aids in the holistic understanding of mental health disorders, reflecting a significant trend toward integrated mental health care solutions in the country.

    Depression Screening Mental Health Market End User Insights

    Depression Screening Mental Health Market End User Insights

    The End User segment of the Japan Depression Screening Mental Health Market encompasses a diverse range of facilities and environments that play a crucial role in mental health evaluation and intervention. Hospitals and Clinics serve as primary hubs for mental health care, providing specialized services and resources imperative in addressing depression. These institutions often include qualified professionals who can administer screenings, ensuring accurate diagnosis and effective treatment pathways. Home-based care, increasingly embraced in Japan, offers an alternative that caters to patients' needs in a comfortable setting, allowing for more personalized and accessible support.

    This method is particularly significant for individuals who may include the elderly or those with mobility challenges, thus expanding the reach of mental health services. Research and Academic Institutes contribute to the market by advancing knowledge on depression screening and fostering innovation in mental health practices. Their role in promoting educational initiatives and establishing evidence-based guidelines is vital for enhancing overall understanding and treatment of depression within Japan. This multifaceted approach within the End User segment highlights a comprehensive effort towards improving mental health outcomes in the region.

    Get more detailed insights about Japan Depression Screening Mental Health Market Research Report - Forecast to 2035

    Request Free Sample

    Regional Insights

    Key Players and Competitive Insights

    The Japan Depression Screening Mental Health Market is characterized by a growing awareness of mental health issues, increased funding for mental health research, and a rising demand for effective screening tools and treatments for depression. As the prevalence of mental health disorders increases, driven by societal pressures, economic factors, and an aging population, various stakeholders are intensifying their efforts to provide comprehensive solutions tailored to this sector. This competitive landscape is marked by the presence of diverse entities ranging from financial institutions and pharmaceuticals to healthcare providers, each contributing to the enhancement of mental health services in Japan. 

    The market is governed by regulatory frameworks that ensure the quality and efficacy of mental health products and services, emphasizing the need for innovation, collaboration, and strategic partnerships to meet emerging demands effectively.Mizuho Financial Group has established a robust presence in the Japan Depression Screening Mental Health Market through its commitment to addressing financial barriers that often hinder access to mental health services. The company's strengths lie in its extensive financial resources and partnerships with various healthcare organizations, enabling it to support initiatives aimed at improving mental health screening and treatment accessibility. 

    Mizuho's financial backing allows for investments in mental health programs and community outreach, which are essential for raising awareness about depression and encouraging early diagnosis. Their collaborative approach promotes mental health literacy across different demographics, fostering an environment that prioritizes the well-being of individuals suffering from depression, ultimately contributing to the market's overall growth.Mitsubishi Tanabe Pharma plays a pivotal role in the Japan Depression Screening Mental Health Market, focusing on the development and promotion of pharmaceutical solutions for mental health disorders. 

    The company offers a range of products designed to improve the diagnosis and treatment of depression, including innovative medications that address various symptoms and help enhance the quality of life for affected individuals. Mitsubishi Tanabe Pharma's strengths include its extensive research and development capabilities, which position it at the forefront of therapeutic advancements in psychiatry. The company's active involvement in strategic partnerships and collaborations enhances its market presence, allowing for better distribution and accessibility of its products. 

    Notably, its mergers and acquisitions in the mental health sector have further strengthened its market position, facilitating robust product portfolios that cater to the unique needs of the Japanese population dealing with depression. Through these initiatives, Mitsubishi Tanabe Pharma remains a key player in promoting mental health and advancing the standards of care in Japan.

    Key Companies in the Japan Depression Screening Mental Health Market market include

    Industry Developments

    In recent months, the Japan Depression Screening Mental Health Market has seen significant activity, shaped by ongoing efforts to enhance mental health initiatives in the country. Recent developments include advancements in digital mental health solutions by companies like Fujitsu and LINE Corporation, focusing on integrating Artificial Intelligence into their screening processes. Notable growth has been observed in the market valuation of companies such as Astellas Pharma and Eisai, reflecting a rising demand for mental health services amid a growing awareness of depression and mental health issues.

    Moreover, in July 2023, Takeda Pharmaceutical announced a strategic partnership with iTHRIVE, aiming to broaden access to depression screening tools. 

    The past couple of years also witnessed major events, including Mitsubishi Tanabe Pharma’s emphasis on Research and Development in depression treatment available in Japan, further underlining the increasing focus on mental health solutions. The Japanese government is also actively promoting better mental health policies, fostering an environment conducive to growth in this market segment. Overall, the combination of corporate activities and public health initiatives is driving evolution within the Japan Depression Screening Mental Health Market.

    Market Segmentation

    Outlook

    • Hospitals and Clinics
    • Home-based
    • Research and Academic Institutes

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2023 34.48(USD Million)
    MARKET SIZE 2024 36.5(USD Million)
    MARKET SIZE 2035 71.0(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 6.235% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED Mizuho Financial Group, Mitsubishi Tanabe Pharma, Astellas Pharma, Fujitsu, Sony, iTHRIVE, Santen Pharmaceutical, NTT Data, Eisai, Otsuka Pharmaceutical, Fujifilm, LINE Corporation, Takeda Pharmaceutical, Daiichi Sankyo, Shionogi
    SEGMENTS COVERED Indication, Diagnosis, End User
    KEY MARKET OPPORTUNITIES Telehealth services expansion, AI-driven screening tools, Workplace mental health programs, Increased awareness and education, Government health initiatives support
    KEY MARKET DYNAMICS increasing mental health awareness, aging population affecting demand, growing digital health adoption, government health initiatives, stigma reduction efforts
    COUNTRIES COVERED Japan

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch
    Leave a Comment

    FAQs

    What is the expected market size of the Japan Depression Screening Mental Health Market in 2024?

    The Japan Depression Screening Mental Health Market is expected to be valued at 36.5 million USD in 2024.

    What will the market size be by 2035?

    By 2035, the Japan Depression Screening Mental Health Market is projected to reach 71.0 million USD.

    What is the compound annual growth rate (CAGR) for the Japan Depression Screening Mental Health Market from 2025 to 2035?

    The market is expected to grow at a CAGR of 6.235% from 2025 to 2035.

    Which indication has the largest market share in 2024 within the Japan Depression Screening Mental Health Market?

    The Major Depressive Disorder indication holds the largest market share valued at 12.5 million USD in 2024.

    What are the projected market sizes for Anxiety Distress from 2024 to 2035?

    The market size for Anxiety Distress is projected to grow from 10.0 million USD in 2024 to 18.5 million USD by 2035.

    Who are the major players in the Japan Depression Screening Mental Health Market?

    Key players in the market include Mizuho Financial Group, Mitsubishi Tanabe Pharma, and Takeda Pharmaceutical among others.

    What is the anticipated market size for Bipolar Disorder in 2035?

    The market size for Bipolar Disorder is expected to reach 13.5 million USD in 2035.

    What challenges are anticipated in the Japan Depression Screening Mental Health Market?

    Challenges in the market may arise from regulatory hurdles and the stigma associated with mental health treatment.

    Is there an emerging trend within the Japan Depression Screening Mental Health Market?

    An emerging trend includes the increased use of digital health tools for patient screening and monitoring.

    What is the growth expectation for Psychotic Disorders in the Japan Depression Screening Mental Health Market by 2035?

    The market for Psychotic Disorders is expected to grow from 5.0 million USD in 2024 to 10.5 million USD by 2035.

    1. EXECUTIVE
    2. SUMMARY
    3. Market Overview
    4. Key Findings
    5. Market Segmentation
    6. Competitive Landscape
    7. Challenges and Opportunities
    8. Future Outlook
    9. MARKET INTRODUCTION
    10. Definition
    11. Scope of the study
    12. Research Objective
    13. Assumption
    14. Limitations
    15. RESEARCH
    16. METHODOLOGY
    17. Overview
    18. Data
    19. Mining
    20. Secondary Research
    21. Primary
    22. Research
    23. Primary Interviews and Information Gathering
    24. Process
    25. Breakdown of Primary Respondents
    26. Forecasting
    27. Model
    28. Market Size Estimation
    29. Bottom-Up
    30. Approach
    31. Top-Down Approach
    32. Data
    33. Triangulation
    34. Validation
    35. MARKET
    36. DYNAMICS
    37. Overview
    38. Drivers
    39. Restraints
    40. Opportunities
    41. MARKET FACTOR ANALYSIS
    42. Value chain Analysis
    43. Porter's
    44. Five Forces Analysis
    45. Bargaining Power of Suppliers
    46. Bargaining
    47. Power of Buyers
    48. Threat of New Entrants
    49. Threat
    50. of Substitutes
    51. Intensity of Rivalry
    52. COVID-19
    53. Impact Analysis
    54. Market Impact Analysis
    55. Regional
    56. Impact
    57. Opportunity and Threat Analysis
    58. Japan
    59. Depression Screening Mental Health Market, BY Indication (USD Million)
    60. Major
    61. Depressive Disorder
    62. Anxiety Distress
    63. Bipolar
    64. Disorder
    65. Psychotic Disorders
    66. Others
    67. Japan
    68. Depression Screening Mental Health Market, BY Diagnosis (USD Million)
    69. Psychological
    70. Tests
    71. Blood Tests
    72. Pharmacogenomic
    73. Testing
    74. Others
    75. Japan
    76. Depression Screening Mental Health Market, BY End User (USD Million)
    77. Hospitals
    78. and Clinics
    79. Home-based
    80. Research
    81. and Academic Institutes
    82. Competitive Landscape
    83. Overview
    84. Competitive
    85. Analysis
    86. Market share Analysis
    87. Major
    88. Growth Strategy in the Depression Screening Mental Health Market
    89. Competitive
    90. Benchmarking
    91. Leading Players in Terms of Number of Developments
    92. in the Depression Screening Mental Health Market
    93. Key
    94. developments and growth strategies
    95. New Product Launch/Service
    96. Deployment
    97. Merger & Acquisitions
    98. Joint
    99. Ventures
    100. Major Players Financial Matrix
    101. Sales
    102. and Operating Income
    103. Major Players R&D Expenditure.
    104. Company
    105. Profiles
    106. Mizuho Financial Group
    107. Financial
    108. Overview
    109. Products Offered
    110. Key
    111. Developments
    112. SWOT Analysis
    113. Key
    114. Strategies
    115. Mitsubishi Tanabe Pharma
    116. Financial
    117. Overview
    118. Products Offered
    119. Key
    120. Developments
    121. SWOT Analysis
    122. Key
    123. Strategies
    124. Astellas Pharma
    125. Financial
    126. Overview
    127. Products Offered
    128. Key
    129. Developments
    130. SWOT Analysis
    131. Key
    132. Strategies
    133. Fujitsu
    134. Financial
    135. Overview
    136. Products Offered
    137. Key
    138. Developments
    139. SWOT Analysis
    140. Key
    141. Strategies
    142. Sony
    143. Financial
    144. Overview
    145. Products Offered
    146. Key
    147. Developments
    148. SWOT Analysis
    149. Key
    150. Strategies
    151. iTHRIVE
    152. Financial
    153. Overview
    154. Products Offered
    155. Key
    156. Developments
    157. SWOT Analysis
    158. Key
    159. Strategies
    160. Santen Pharmaceutical
    161. Financial
    162. Overview
    163. Products Offered
    164. Key
    165. Developments
    166. SWOT Analysis
    167. Key
    168. Strategies
    169. NTT Data
    170. Financial
    171. Overview
    172. Products Offered
    173. Key
    174. Developments
    175. SWOT Analysis
    176. Key
    177. Strategies
    178. Eisai
    179. Financial
    180. Overview
    181. Products Offered
    182. Key
    183. Developments
    184. SWOT Analysis
    185. Key
    186. Strategies
    187. Otsuka Pharmaceutical
    188. Financial
    189. Overview
    190. Products Offered
    191. Key
    192. Developments
    193. SWOT Analysis
    194. Key
    195. Strategies
    196. Fujifilm
    197. Financial
    198. Overview
    199. Products Offered
    200. Key
    201. Developments
    202. SWOT Analysis
    203. Key
    204. Strategies
    205. LINE Corporation
    206. Financial
    207. Overview
    208. Products Offered
    209. Key
    210. Developments
    211. SWOT Analysis
    212. Key
    213. Strategies
    214. Takeda Pharmaceutical
    215. Financial
    216. Overview
    217. Products Offered
    218. Key
    219. Developments
    220. SWOT Analysis
    221. Key
    222. Strategies
    223. Daiichi Sankyo
    224. Financial
    225. Overview
    226. Products Offered
    227. Key
    228. Developments
    229. SWOT Analysis
    230. Key
    231. Strategies
    232. Shionogi
    233. Financial
    234. Overview
    235. Products Offered
    236. Key
    237. Developments
    238. SWOT Analysis
    239. Key
    240. Strategies
    241. References
    242. Related
    243. Reports
    244. LIST
    245. OF ASSUMPTIONS
    246. Japan Depression Screening Mental Health
    247. Market SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2035 (USD Billions)
    248. Japan
    249. Depression Screening Mental Health Market SIZE ESTIMATES & FORECAST, BY DIAGNOSIS,
    250. 2035 (USD Billions)
    251. Japan Depression Screening Mental
    252. Health Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    253. PRODUCT
    254. LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    255. ACQUISITION/PARTNERSHIP
    256. LIST
    257. Of figures
    258. MARKET SYNOPSIS
    259. JAPAN
    260. DEPRESSION SCREENING MENTAL HEALTH MARKET ANALYSIS BY INDICATION
    261. JAPAN
    262. DEPRESSION SCREENING MENTAL HEALTH MARKET ANALYSIS BY DIAGNOSIS
    263. JAPAN
    264. DEPRESSION SCREENING MENTAL HEALTH MARKET ANALYSIS BY END USER
    265. KEY
    266. BUYING CRITERIA OF DEPRESSION SCREENING MENTAL HEALTH MARKET
    267. RESEARCH
    268. PROCESS OF MRFR
    269. DRO ANALYSIS OF DEPRESSION SCREENING
    270. MENTAL HEALTH MARKET
    271. DRIVERS IMPACT ANALYSIS: DEPRESSION
    272. SCREENING MENTAL HEALTH MARKET
    273. RESTRAINTS IMPACT ANALYSIS:
    274. DEPRESSION SCREENING MENTAL HEALTH MARKET
    275. SUPPLY / VALUE
    276. CHAIN: DEPRESSION SCREENING MENTAL HEALTH MARKET
    277. DEPRESSION
    278. SCREENING MENTAL HEALTH MARKET, BY INDICATION, 2025 (% SHARE)
    279. DEPRESSION
    280. SCREENING MENTAL HEALTH MARKET, BY INDICATION, 2019 TO 2035 (USD Billions)
    281. DEPRESSION
    282. SCREENING MENTAL HEALTH MARKET, BY DIAGNOSIS, 2025 (% SHARE)
    283. DEPRESSION
    284. SCREENING MENTAL HEALTH MARKET, BY DIAGNOSIS, 2019 TO 2035 (USD Billions)
    285. DEPRESSION
    286. SCREENING MENTAL HEALTH MARKET, BY END USER, 2025 (% SHARE)
    287. DEPRESSION
    288. SCREENING MENTAL HEALTH MARKET, BY END USER, 2019 TO 2035 (USD Billions)
    289. BENCHMARKING
    290. OF MAJOR COMPETITORS

    Japan Depression Screening Mental Health Market Segmentation

    • Depression Screening Mental Health Market By Indication (USD Million, 2019-2035)

      • Major Depressive Disorder
      • Anxiety Distress
      • Bipolar Disorder
      • Psychotic Disorders
      • Others

     

    • Depression Screening Mental Health Market By Diagnosis (USD Million, 2019-2035)

      • Psychological Tests
      • Blood Tests
      • Pharmacogenomic Testing
      • Others

     

    • Depression Screening Mental Health Market By End User (USD Million, 2019-2035)

      • Hospitals and Clinics
      • Home-based
      • Research and Academic Institutes

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027